AcelRx Pharmaceuticals Inc (ACRX) Receives Average Rating of “Buy” from Brokerages

Share on StockTwits

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has received an average rating of “Buy” from the eleven analysts that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $7.44.

A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, April 26th. B. Riley assumed coverage on shares of AcelRx Pharmaceuticals in a research report on Wednesday, April 24th. They issued a “buy” rating and a $6.50 price objective for the company. BidaskClub upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 1st. LADENBURG THALM/SH SH restated a “buy” rating and issued a $10.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Thursday, May 9th. Finally, ValuEngine lowered shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th.

NASDAQ:ACRX traded up $0.10 on Thursday, reaching $2.96. 1,014,596 shares of the company’s stock were exchanged, compared to its average volume of 2,073,677. The company has a quick ratio of 4.91, a current ratio of 5.03 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $229.25 million, a PE ratio of -3.65 and a beta of 2.16. AcelRx Pharmaceuticals has a 52 week low of $1.99 and a 52 week high of $5.05.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.85 million. Analysts anticipate that AcelRx Pharmaceuticals will post -0.84 earnings per share for the current fiscal year.

In related news, Director Mark G. Edwards bought 19,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were acquired at an average cost of $2.99 per share, with a total value of $56,810.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders bought 26,721 shares of company stock valued at $78,506 over the last 90 days. 25.50% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Resources Investment Advisors Inc. purchased a new stake in AcelRx Pharmaceuticals in the first quarter valued at approximately $34,000. First National Bank of Mount Dora Trust Investment Services purchased a new stake in AcelRx Pharmaceuticals in the first quarter valued at approximately $70,000. Jane Street Group LLC purchased a new stake in AcelRx Pharmaceuticals in the first quarter valued at approximately $91,000. Charles Schwab Investment Management Inc. raised its stake in AcelRx Pharmaceuticals by 93.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 28,438 shares of the specialty pharmaceutical company’s stock valued at $99,000 after purchasing an additional 13,738 shares in the last quarter. Finally, Raymond James & Associates raised its stake in AcelRx Pharmaceuticals by 96.7% in the fourth quarter. Raymond James & Associates now owns 29,500 shares of the specialty pharmaceutical company’s stock valued at $68,000 after purchasing an additional 14,500 shares in the last quarter. 18.57% of the stock is currently owned by institutional investors and hedge funds.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Recommended Story: What is the Consumer Price Index (CPI)?

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Full Sail Capital LLC Purchases Shares of 14,240 iShares MSCI Germany ETF
Full Sail Capital LLC Purchases Shares of 14,240 iShares MSCI Germany ETF
2,651 Shares in ProShares Ultra QQQ  Acquired by Meridian Wealth Management LLC
2,651 Shares in ProShares Ultra QQQ Acquired by Meridian Wealth Management LLC
Meridian Wealth Management LLC Buys Shares of 2,536 Alexion Pharmaceuticals, Inc.
Meridian Wealth Management LLC Buys Shares of 2,536 Alexion Pharmaceuticals, Inc.
Thor Advisors LLC Purchases New Position in Coty Inc
Thor Advisors LLC Purchases New Position in Coty Inc
763 Shares in Principal Financial Group Inc  Purchased by Thor Advisors LLC
763 Shares in Principal Financial Group Inc Purchased by Thor Advisors LLC
Brokerages Set AAR Corp.  PT at $49.50
Brokerages Set AAR Corp. PT at $49.50


 
© 2006-2019 Zolmax.